UltraV, a biomedical beauty group, recently announced that UltraCol, developed by its proprietary patented technology, has been acquired a product approval by the Malaysian Medical Device Authority (MDA).

Positioned as a major medical center in Asia, Malaysia is gaining traction as a strategic location to enter the Islamic market, driven by a flourishing middle class and a growing interest in beauty enhancements. The medical device sector in Malaysia is projected to reach around US$2.72 billion by 2027 and is anticipated to experience consistent growth in the upcoming years. 

Malaysia is now open to receiving our product UltraCol through our official distributor Neuva Era, thanks to the approval we have received. This will make it possible for local clinics to import larger consignments, introducing the superior quality and safety of UltraCol to Malaysia, and proactively increasing our market presence.

Expanding its global presence is a top priority for the company, and it intends to achieve this by securing approvals in countries across the world, including Asia, South America, the Middle East, and Europe, strengthening its presence in local markets by hosting academic forums and lectures at conferences.

An official from Ultra V said, "Our main goal is to increase our presence in the global market,

driving sales and elevating our brand", "Based on our years of experience in overseas expansion, we will make every effort to lead the Malaysian medical device market by establishing localized strategies and conducting extensive marketing."

UltraColl is based on polydioxanone (PDO), the same ingredient as the melting thread. When fibroblasts and collagen fibers are rearranged around the PDO filler particles the filler particles are decomposed and the regeneration of collagen fibers is induced to improve skin elasticity.

Ultracol is characterized by its high biodegradability, which means that there is no burden of residue in the body as it is naturally absorbed and decomposed in the body, It has been recognized for excellence in the world's first PDO filler manufacturing and mass production technology, won the 'IR52 Jang Yeong Sil Prize' in 2020 for exclusive patent technique and won the Korean Patent Grand Prize, as well as KFDA certification and European CE certification.

With the recent completion of the official licensing in Hainan Province from China's NMPA (National Medical Products Administration), the company plans to continue its high-end strategy to focus on the Chinese market with the stability, high quality, and technology of 'UltraCol'.